

SECOND TRADEMARKS PTO FORM-1449 INFORMATION DISCLOSURE CITATION		Inventor: KAUTZ	Art Unit: XX		
		Appl. No.: 10/590,803	Examiner: XX		
		Filing Date: August 25, 2006	Confirm. No.: XX		
U. S. PATENT DOCUMENTS					
Exam. Initial		Document No.	Issue/Public. Date	Inventor	Filed Date
FOREIGN PATENT DOCUMENTS					
Exam. Initial		Document No.	Public. Date	Country	Translation
OTHER					
Exam. Initial	(Including Author, Title, Date, Pertinent Pages, etc.)				
	A34	Souness, J.E., "Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors", <u>Immunopharmacology</u> , Vol. 47, Pg. 127-162, (2000).			
	A35	Dyke, H.J., et al., "Update on the therapeutic potential of PDE4 inhibitors", <u>Expert Opin. Investig. Drugs</u> , Vol. 11, No. 1, Pg. 1-13, (2002).			
	A36	Montana, J.G., et al., "Chapter 5. Phosphodiesterase 4 Inhibitors", <u>Annual Reports in Medicinal Chemistry</u> , Vol. 36, Pg. 41-56, (2001).			
	A37	Schmidt, B.M.W., et al., "The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis", <u>J Allergy Clin Immunol</u> , Vol. 108, Pg. 530-536, (2001).			
Examiner			Date Considered		

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP' 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.